From Your Arm to the Lab: The Journey of Your NK Cells in Japan

Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.

When considering advanced treatments like NK cell therapy, it’s natural to have questions about the process. One of the most common is: “What exactly happens to my blood after it’s drawn?” Understanding the journey your cells take—from your arm, to a specialized laboratory, and back into your body—can provide clarity and peace of mind. This article traces the meticulous process of autologous NK cell therapy in Japan, shedding light on the stringent safety and quality control measures that govern every step.

Understanding the NK Cell Therapy Journey

The entire process of NK cell therapy is designed with patient safety and treatment quality as the highest priorities. In essence, a sample of your own blood is used to isolate Natural Killer (NK) cells, which are then activated and multiplied in a highly controlled laboratory environment before being returned to your body. This journey is carefully managed under Japan’s Act on the Safety of Regenerative Medicine, ensuring that each stage adheres to strict national standards. Let’s explore this path step by step.

Step 1: Consultation and Blood Collection

Your journey begins with a thorough consultation with a physician. This is a crucial step to discuss your health condition, treatment goals, and to determine if NK cell therapy is a suitable option for you. A doctor will explain the potential benefits, limitations, risks, and side effects. It is important to remember that a physician’s diagnosis is required to proceed.

If you and your doctor decide to move forward, the first clinical step is a simple blood draw, much like one you would have for a routine health check. A specific amount of your blood is collected into sterile containers. This sample contains various immune cells, including the NK cells that will be the focus of the therapy.

Step 2: From Clinic to Cell Processing Center (CPC)

Once collected, your blood sample is immediately prepared for secure, temperature-controlled transport to a specialized facility known as a Cell Processing Center (CPC). These are not ordinary laboratories; CPCs are highly sophisticated facilities that must be licensed by Japan’s Ministry of Health, Labour and Welfare to handle and culture cells for therapeutic use. Strict protocols for transportation and handling ensure the viability and integrity of your cells from the moment they leave the clinic.

Step 3: Cell Isolation, Culturing, and Expansion

Inside the CPC, your sample undergoes a meticulous process within a sterile, clean-room environment. First, the NK cells are carefully isolated from the other components of your blood. This is a critical step to ensure the final product is concentrated with the desired immune cells.

Next, the isolated NK cells are placed in a special culture medium containing nutrients and stimulating factors (like cytokines) that encourage them to activate and multiply. Over a period of several weeks, the small number of NK cells from your initial blood sample proliferates into a large, highly active population. Technicians continuously monitor the culture to ensure optimal growth and health of the cells. The entire process is managed in a closed system to minimize any risk of contamination.

Step 4: Rigorous Quality and Safety Assurance

Before the expanded NK cells are approved for release, they must pass a series of rigorous quality and safety tests. This is a non-negotiable step mandated by Japanese regulations. The tests confirm several key parameters:

• Identity and Purity: Verifying that the cultured cells are indeed NK cells and that the population is sufficiently pure.
• Potency: Assessing the activity level of the NK cells to ensure they are capable of their intended function.
• Viability: Confirming that a high percentage of the cells are alive and healthy.
• Sterility: Testing for the absence of bacteria, fungi, viruses, and other contaminants.
• Cell Count: Ensuring the final product contains the target number of cells for the therapy.

Only after passing all these checks are the cells deemed ready to be returned to the patient.

Step 5: Return to the Clinic and Administration

The final product—a solution containing your own highly active and numerous NK cells—is securely transported back to the clinic. The therapy is administered through a simple intravenous (IV) drip, a process that typically takes about an hour. Because the therapy uses your own (autologous) cells, the risk of rejection-related reactions is considered low. Patients can usually return to their daily activities shortly after the infusion, as hospitalization is generally not required.

Considering NK Cell Therapy in Osaka

The journey of your NK cells is a testament to the precision and safety embedded in Japan’s regenerative medicine framework. This process aims to support the body’s natural defenses and can be used in conjunction with standard cancer treatments, but it is not a replacement for them. It is important to note that NK cell therapy is provided as an out-of-pocket medical service and is not covered by public health insurance.

At Grand Green Osaka Umekita Clinic, we are committed to providing clear information to help you make an informed decision. The suitability, specific protocol, number of treatments, and costs must be discussed and determined with a physician based on your individual circumstances. We encourage you to review all aspects of the treatment, including the potential risks and side effects, during your consultation.

For a more detailed overview of the treatment flow, features, and frequently asked questions, please visit our comprehensive NK Cell Therapy information page. Our team in Osaka is here to support you in understanding your options.

1. 1Consult & Blood DrawYour journey starts at the clinic after a consultation
2. 2Cell Culturing & ExpansionNK cells are multiplied in a specialized lab (CPC)
3. 3Quality & Safety ChecksRigorous testing is performed under national standards
4. 4Administration by IV DripYour own activated cells are returned to your body

This diagram provides a simplified overview of the process described in the article

References

• PMC: Automated and closed clinical-grade manufacturing protocol produces potent NK cells against neuroblastoma cells and AML blasts. (2024)
• PMC: CAR-NK cells: A promising cellular immunotherapy for cancer. (2020)
• PMC: Closed-system manufacturing of therapeutic NK cells using automated cell enrichment and concentration processes enables scalable, robust and cost-effective solutions. (2025)
• PMC: Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies. (2015)
• MHLW (Japan): Regenerative Medicine — Ministry of Health, Labour and Welfare, Japan

Supervising Physician

Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic

Hidenori Shimada

Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.

* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.